model (Cox, 1972) was assumed. Here, the term 'hazard' refers mainly to the mortality rate. The only exception is when adjustment was made for natural mortality in evaluating the prognostic value of age and sex when a proportional 'excess mortality' model was used, i.e. mortality in excess of that expected in a group of the same age and sex composition in the general population. The latter was estimated using the 1984 rates for England and Wales (OPCS, 1985). The long duration of the trial and the relatively old age of the patients in this series (median age 69 years) prompted us to take natural mortality into consideration. This adjustment was not made when the prognostic effects of factors other than age and sex were evaluated, as all the analyses involving non-demographic factors were adjusted for age and sex.
Between 1978 and 1987, 400 patients with T3 MO bladder tumours were entered into a multicentre randomised prospective trial of neo-adjuvant and maintenance chemotherapy. Details of the trial, the treatment arms, and the preliminary results are published elsewhere (Co-operative Urological Cancer Group, 1988) . There was no difference in survival between the two arms of the trial. The notification (or entry) form for the trial contained information on potential prognostic variables and in this paper we examine these factors in detail. We also wished to investigate the effect on survival of allowing for general population mortality in this elderly group of patients.
Patients and methods
This analysis is based on 394 patients (for whom we had notification forms) presenting with T3 MO bladder cancer and randomised between June 1978 and January 1987 in a multicentre randomised trial organised by the Co-operative Urological Cancer Group. Of these patients, 319 were treated by radical radiotherapy, 75 by preoperative radiotherapy and radical cystectomy and 197 patients had adjuvant methotrexate as well as local treatment as detailed in the trial report (Sheare et al., 1988 Product-limit estimates (Kaplan & Meier, 1958) were used for survival curves, and 95% confidence intervals (CI) for survival probabilities calculated. A proportional hazard model (Cox, 1972) 'l <~~--~~l Figure lb gives the survival curves for the two groups. The data do not provide evidence of a significant effect of tumour appearance and cell type on prognosis. The lack of evidence for the latter variable may be due to the small number of patients with squamous cell carcinoma.
Investigation of the joint prognostic effect of the above variables revealed a very significant interaction between tumour size and nodal status (X2=10.50, d.f.=2, P=0.005). Table III gives the mortality rate ratios for the combinations of the levels of these two factors. The rate ratios are relative to the node-negative small tumour category. The positive and highly significant trend in mortality rate with tumour size (x2 = 12.70, d.f. = 1, P<0.0005) when there is no involvement of the local lymph nodes is contrasted with an apparent negative trend among the node-positive patients. However, this negative trend in the latter group is not statistically significant (X2=2.42, d.f.= 1, P>0.1). Further analysis of this interaction showed that more than 90% of its effect (as measured by x2 = 10.50, d.f. = 2) was due to the difference in the prognostic effect of nodal status within patients with large tumours on the one hand, and small or moderate tumours on the other hand. Furthermore, there was no significant difference in mortality rate between nodepositive and node-negative patients with large tumours. This suggested that primary tumour size and nodal status might Figure 2 Survival by prognostic group: group 1, nodenegative and small tumour; ------group 2, node-negative and moderate tumour; .*--group 3, node-positive and/or large tumour.
be combined into the following prognostic groupings: (1) node-negative and small tumour; (2) node-negative and moderate tumour; (3) node-positive or large tumour. The mortality rate ratios for these groups are given in Table IV and the corresponding survival curves in Figure 2 . The mortality rate is approximately doubled from one level to the next. The predictive power is measured by the highly significant trend (X2 = 16.40, d.f. = 1, P<0.0001).
Discussion
Conflicting results have been reported on the prognostic effect of age and gender (Bloom et al., 1982; Narayana et al., 1983; Pryor, 1973; Blandy et al., 1980) . In terms of (unadjusted) survival, the present series showed a significant negative trend in survival rate with age (younger patients faring better than older ones) and weak evidence of poorer prognosis for men as compared to women. However, after correcting for natural mortality, the adjusted rates showed no significant dependence on age or sex. The material influence of natural mortality is due to the old age of the patients entered and the length of the follow-up period. Our findings highlight the need for taking natural mortality into account when investigating prognostic factors in trials of moderate length with elderly patients. A simple way of achieving this is to adjust the analysis for age and sex even if the influence of age and sex is not statistically significant, Alternatively, the analysis could be based on mortality specific to the disease under study. This can be more efficient if the disease specific mortality is much lower than natural mortality from all causes, but it is of less value when the recorded cause of death is not very accurate, as is sometimes the case, particularly in elderly patients and in situations when death from other causes may be indirectly related to the study disease or its treatment. In the present series 202 patients have died from bladder cancer, seven from postoperative complications and 51 from other causes. The number of deaths from causes other than bladder cancer or operative mortality was significantly higher than the total number expected (36.5) from all cause natural mortality (P=0.01), suggesting, as expected, that these deaths were bladder cancer related.
Invasive papillary carcinomas are reported to be more radiosensitive, less likely to spread to the pelvic nodes and confer more favourable prognosis than invasive solid tumours (Slack & Prout, 1980; Heney et al., 1983) . In the present series, nodal status was recorded for 17 patients with papillary tumours, of whom five (23%) were node positive. The corresponding figure for 109 patients with solid tumours and ascertained nodal status was 34 (24%), providing no evidence of a difference in the tendency to metastasise locally. Similarly there was no overall survival difference in the two groups (see Figure 1c) .
Although the mortality rate in the few patients with squamous cell tumours was 70% higher than in those with transitional cell tumours, there is little evidence of a real survival difference Figure Id) . This may be due to the small number of patients in the former group (11 patients with squamous cell carcinoma versus 325 with transitional cell carcinoma).
The poor performance of large primary tumours has been reported by Narayana et al. (1983) and, at least within one treatment arm, by Bloom et al. (1982) . We found that the presentation size of the primary tumour was the single most important prognostic factor. The mortality rates for small, moderate and large tumours were, on average, in the ratios 1:1.5:2.
Metastasis to the regional lymph nodes is well recognised as an indicator of poor prognosis. Smith & Whitmore (1981) reported 7% 5-year survival in 134 node-positive patients. Heney et al. (1983) found 3% 5-year survival in 23 nodepositive patients compared to 41% in 59 node-negative patients, while Bloom et al. (1982) reported 18 and 53% (corrected) 5-year survival for the two groups. Our data confirm these findings. We found nodal status to be the second most important prognostic variable. On average, node-positive patients experienced a 70% higher mortality rate than node-negative patients.
Primary tumour size and nodal status do not appear to act independently. We found a very significant interaction between the effects of these two variables on prognosis. A highly significant positive trend in mortality with tumour size in node-negative patients is in contrast to a negative though not quite significant trend in node-positive patients. The fact that the latter is not statistically significant suggests that the nature of this interaction is likely to be quantitative rather than qualitative, where by a 'quantitative interaction' between two factors A and B, we mean a situation where there is variation in magnitude, but not in direction, of the effect of A among the levels defined by B and vice-versa. The situation where there is reversal of direction is termed qualitative or cross-over interaction. One possible explanation for the lack of any difference in mortality rate between node-positive and node-negative patients with large tumours is that involvement of the lymph nodes tends to be underdetected in general, and that large tumours are much more likely to have metastasised to the local lymph nodes than small or moderate tumours.
Based on the above findings, we propose the following prognostic groupings: (1) node-negative and small primary tumour; (2) node-negative and moderate primary tumour; (3) node-positive or large primary tumour. This grouping accounted for more than 75% of all variation in survival accounted for by all the six variables and their first order interactions. However, the true performance of this grouping can only be judged on independent data.
